APA (7th ed.) Citation

K, S., & M, N. (2026). Strategic Integration of Companion Diagnostics in Precision Oncology: Key Factors, Drug Development Timelines, and Regulatory Insights from U.S. FDA Approvals. Therapeutic innovation & regulatory science, 60(4), 983. https://doi.org/10.1007/s43441-026-00917-z

Chicago Style (17th ed.) Citation

K, Saito, and Narukawa M. "Strategic Integration of Companion Diagnostics in Precision Oncology: Key Factors, Drug Development Timelines, and Regulatory Insights from U.S. FDA Approvals." Therapeutic Innovation & Regulatory Science 60, no. 4 (2026): 983. https://doi.org/10.1007/s43441-026-00917-z.

MLA (9th ed.) Citation

K, Saito, and Narukawa M. "Strategic Integration of Companion Diagnostics in Precision Oncology: Key Factors, Drug Development Timelines, and Regulatory Insights from U.S. FDA Approvals." Therapeutic Innovation & Regulatory Science, vol. 60, no. 4, 2026, p. 983, https://doi.org/10.1007/s43441-026-00917-z.